A SCOTTISH firm developing medicines for those living with Parkinson’s has been awarded a major funding boost from the Michael J Fox Foundation (MJFF).
The Edinburgh-based Lario Therapeutics, a company developing medicines for epileptic and neurological disorders, was awarded a $6 million (£4.7m) grant from the Back to the Future star’s foundation.
The Hollywood star was diagnosed with early on-set Parkinson’s disease in 1991, aged just 29, and set up the foundation in 2000.
READ MORE: Sky News hosts slam Labour ministers for ducking media scrutiny
Lario has said the grant will fund its preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of the disease.
Researchers say there is extensive study linking calcium channels to pathology of the disease, and preclinical experimental studies have shown that the deletion of CaV2.3 can help protect against Parkinson’s.
Tom Otis, chief scientific officer of Lario Therapeutics, said: “We are grateful to MJFF for their funding support for Lario’s efforts to test and develop a potential new therapy designed to prevent the loss of neurons that causes Parkinson’s disease.
“If our research is successful, this will represent an important new treatment option for patients.”
Henning Steinhagen, co-founder and chief executive of Lario Therapeutics, said: “This significant funding from MJFF will aid the work out of our therapeutic pipeline and the work we have achieved so far in advancing research in the field.
“This grant will help drive our ambition to progress our CaV2.3 program swiftly towards the clinic, to provide a new, effective treatment option for people with Parkinson’s disease.”
Gaia Skibinski, director of research programs at MJFF, added: “MJFF is dedicated to funding innovative research, such as the work done at Lario Therapeutics, to develop a pipeline of novel therapies that can improve the lives of people with Parkinson’s disease.
“We look forward to seeing the results of Lario’s research on CaV2.3 as a novel disease-modifying approach for Parkinson’s.”
The programme is partnering with Professor Richard Wade-Martins and the Oxford Parkinson’s Disease Centre (OPDC) for the study.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here